Commentary on: The use of burosumab to treat autosomal-recessive hypophosphatemic rickets type 2: rationale and a first clinical experience
2024

Commentary on Burosumab for Hypophosphatemic Rickets

Commentary

Author Information

Author(s): Frank Rutsch, Isidro B. Salusky, Carlos R. Ferreira

Primary Institution: Muenster University Children’s Hospital

Conclusion

The use of burosumab in treating autosomal recessive hypophosphatemic rickets type 2 should be approached with caution due to potential cardiovascular risks.

Supporting Evidence

  • Burosumab treatment may worsen arterial calcifications in some patients.
  • Many patients with autosomal recessive hypophosphatemic rickets type 2 may have cardiovascular involvement.
  • Current imaging techniques may miss early vascular calcifications in children.

Takeaway

This article talks about a medicine called burosumab that helps kids with a bone disease, but it warns that it might cause heart problems.

Potential Biases

There is a potential bias due to the author's conflict of interest with grant support and consultancy fees from Inozyme Pharma.

Limitations

The commentary highlights that the findings are based on a case report and may not apply to all patients.

Digital Object Identifier (DOI)

10.1007/s40620-024-02057-9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication